A High-Fat Diet Increases Influenza A Virus-Associated Cardiovascular Damage.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
04 08 2020
Historique:
received: 07 02 2020
accepted: 02 04 2020
pubmed: 5 4 2020
medline: 3 3 2021
entrez: 5 4 2020
Statut: ppublish

Résumé

Influenza A virus (IAV) causes a wide range of extrarespiratory complications. However, the role of host factors in these complications of influenza virus infection remains to be defined. Here, we sought to use transcriptional profiling, virology, histology, and echocardiograms to investigate the role of a high-fat diet in IAV-associated cardiac damage. Transcriptional profiling showed that, compared to their low-fat counterparts (LF mice), mice fed a high-fat diet (HF mice) had impairments in inflammatory signaling in the lung and heart after IAV infection. This was associated with increased viral titers in the heart, increased left ventricular mass, and thickening of the left ventricular wall in IAV-infected HF mice compared to both IAV-infected LF mice and uninfected HF mice. Retrospective analysis of clinical data revealed that cardiac complications were more common in patients with excess weight, an association which was significant in 2 out of 4 studies. Together, these data provide the first evidence that a high-fat diet may be a risk factor for the development of IAV-associated cardiovascular damage and emphasizes the need for further clinical research in this area.

Sections du résumé

BACKGROUND
Influenza A virus (IAV) causes a wide range of extrarespiratory complications. However, the role of host factors in these complications of influenza virus infection remains to be defined.
METHODS
Here, we sought to use transcriptional profiling, virology, histology, and echocardiograms to investigate the role of a high-fat diet in IAV-associated cardiac damage.
RESULTS
Transcriptional profiling showed that, compared to their low-fat counterparts (LF mice), mice fed a high-fat diet (HF mice) had impairments in inflammatory signaling in the lung and heart after IAV infection. This was associated with increased viral titers in the heart, increased left ventricular mass, and thickening of the left ventricular wall in IAV-infected HF mice compared to both IAV-infected LF mice and uninfected HF mice. Retrospective analysis of clinical data revealed that cardiac complications were more common in patients with excess weight, an association which was significant in 2 out of 4 studies.
CONCLUSIONS
Together, these data provide the first evidence that a high-fat diet may be a risk factor for the development of IAV-associated cardiovascular damage and emphasizes the need for further clinical research in this area.

Identifiants

pubmed: 32246148
pii: 5815741
doi: 10.1093/infdis/jiaa159
doi:

Substances chimiques

Cytokines 0
G1p2 protein, mouse 0
Hif1a protein, mouse 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
IL1B protein, mouse 0
Interferon Regulatory Factor-7 0
Interleukin-1beta 0
Irf7 protein, mouse 0
RNA, Viral 0
Ubiquitins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

820-831

Subventions

Organisme : Medical Research Council
ID : MC_G1001212
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R005982/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Jurre Y Siegers (JY)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Boris Novakovic (B)

Epigenetics Research, Murdoch Children's Research Institute and Department of Paediatrics, University of Melbourne, Parkville, Australia.

Katina D Hulme (KD)

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.

Rebecca J Marshall (RJ)

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.

Conor J Bloxham (CJ)

School of Biomedical Science, The University of Queensland, Brisbane, Australia.

Walter G Thomas (WG)

School of Biomedical Science, The University of Queensland, Brisbane, Australia.

Mellissa E Reichelt (ME)

School of Biomedical Science, The University of Queensland, Brisbane, Australia.

Lonneke Leijten (L)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Peter van Run (P)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Karen Knox (K)

Preclinical Imaging Facility, Translational Research Institute Australia, Brisbane, Australia.

Kamil A Sokolowski (KA)

Preclinical Imaging Facility, Translational Research Institute Australia, Brisbane, Australia.

Brian W C Tse (BWC)

Preclinical Imaging Facility, Translational Research Institute Australia, Brisbane, Australia.

Keng Yih Chew (KY)

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.

Angelika N Christ (AN)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.

Greg Howe (G)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.

Timothy J C Bruxner (TJC)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.

Mario Karolyi (M)

Department for Infectious Diseases, Kaiser Franz Josef Hospital, Vienna, Austria.

Erich Pawelka (E)

Department for Infectious Diseases, Kaiser Franz Josef Hospital, Vienna, Austria.

Rebecca M Koch (RM)

Radboud University Medical Center, Department of Intensive Care Medicine, Nijmegen, the Netherlands.

Rosa Bellmann-Weiler (R)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Francesco Burkert (F)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Günter Weiss (G)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

Romit J Samanta (RJ)

Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.

Peter J M Openshaw (PJM)

Respiratory Infection Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Helle Bielefeldt-Ohmann (H)

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Australia.

Debby van Riel (D)

Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.

Kirsty R Short (KR)

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH